Integrated analysis of gene expression and tumor nuclear image profiles associated with chemotherapy response in serous ovarian carcinoma

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Liu, Yuexin ^a   Sun, Yan ^a,b   Broaddus, Russell ^a   Liu, Jinsong ^a   Sood, Anil K ^a   Shmulevich, Ilya ^c   Zhang, Wei ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b TIANJIN MEDICAL UNIVERSITY   (China)

^c INSTITUTE FOR SYSTEMS BIOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

A2M GENE; ADULT; AGED; AQP5 GENE; AREG GENE; ARTICLE; AVIL GENE; CALML3 GENE; CANCER CHEMOTHERAPY; CANCER MORPHOLOGY; CANCER PROGNOSIS; CD38 GENE; CNN2 GENE; CONTROLLED STUDY; CXCR4 GENE; DDR1 GENE; DKK1 GENE; DOWN REGULATION; EFNB2 GENE; EPHB3 GENE; EVI1 GENE; FEMALE; FOXA2 GENE; GAP43 GENE; GDF6 GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC DATABASE; GFRA1 GENE; HES1 GENE; HUMAN; HUMAN TISSUE; ICAM5 GENE; IGFBP5 GENE; IGHM GENE; IGKC GENE; IL15 GENE; IMAGING; KCNH2 GENE; LIPG GENE; MAJOR CLINICAL STUDY; MATK GENE; MDK GENE; MMP1 GENE; NPAS3 GENE; NPY GENE; NRG4 GENE; NTF5 GENE; ONCOGENE; OVARY CARCINOMA; OVERALL SURVIVAL; PAX6 GENE; PCSK6 GENE; POU2AF1 GENE; POU5F1 GENE; PROGRESSION FREE SURVIVAL; RTN4R GENE; S100A4 GENE; SD11B2 GENE; SENSITIVITY AND SPECIFICITY; SEROSA; SIGNAL NOISE RATIO; SLC1A3 GENE; SPOCK2 GENE; TREATMENT RESPONSE; TRPV6 GENE; TSPAN7 GENE; TUMOR VOLUME; UPREGULATION; VALIDATION PROCESS; XBP1 GENE; BIOLOGICAL MODEL; DRUG RESISTANCE; METABOLISM; OVARY TUMOR; PATHOLOGY;

ADULT; AGED; AGED, 80 AND OVER; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MODELS, BIOLOGICAL; OVARIAN NEOPLASMS;

EID: 84860674392     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0036383     Document Type: Article

References (41)

1. Jemal A, Siegel R, Xu J, (2010) Cancer Statistics, 2010. CA Cancer J Clin 60: 277-300.
2. National Cancer Institue website. 20 Comprehensive Cancer Information - Available: http://www.cancer.gov/cancertopics/types/ovarian. Accessed 2010 Oct.
3. Cannistra SA, (2004) Cancer of the ovary. N Engl J Med 351: 2519-2529.
4. Selvanayagam ZE, Cheung TH, Wei N, Chin KV, (2004) Prediction of chemotherapeutic response in ovarian cancer with DNA microarray expression profiling. Cancer Genetics and Cytogenetics 154: 63-661.
5. Bachvarov D, L'esperance S, Popa I, Bachvarova M, Plante M, et al. (2006) Gene expression patterns of chemoresistant and chemosensitive serous epithelial ovarian tumors with possible predictive value in response to initial chemotherapy. Int J Oncol 29: 919-933.
6. Dressman HK, Berchuck A, Chan G, Zhai J, Bild A, et al. (2007) An integrated genomic-based approach to individualized treatmetn of patients with advanced-sage ovarian cancer. Journal of Clinical Oncology 25: 517-525.
7. Hartmann LC, Lu KH, Linette GP, Damokosh AI, (2005) Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy. Clinical Cancer Research 11: 2149-2155.
8. Helleman J, Jansen MP, Span PN, Staveren IL, Berns EM, (2006) Molecular profiling of platinum resistant ovarian cancer. Int J Cancer 118: 1963-1971.
9. Jazaeri AA, Awtrey CS, Chandramouli GV, Zorn KK, Boyd J, (2005) Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers. Clin Cancer Res 11: 6300-6310.
10. Peters D, Freund J, Ochs RL, (2005) Genome-wide transcriptional analysis of carboplatin response in chemosensitive and chemoresistant ovarian cancer cells. Mol Cancer Ther 4: 1605-1616.
11. Spentzos D, Levine DA, Ramoni MF, Joseph M, Gu X, et al. (2004) Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J of Clinical Oncology 22: 4700-4710.
12. Spentzos D, Levine DA, Kolia S, Otu H, Boyd J, et al. (2005) Unique gene expression profile based on pathologic response in epithelial ovarian cancer. J of Clinical Oncology 23: 7911-7918.
13. Ozols RF, Bookman MA, Connolly DC, Daly MB, Godwin AK, et al. (2004) Focus on epithelial ovarian cancer. Cancer Cell 5: 19-24.
14. Helleman J, Smid M, Jansen MP, Burg ME, Berns EM, (2010) Pathway analysis of gene lists associated with platinum-based chemotherapy resistance in ovarian cancer: The big picture. Gynecologic Oncology 117: 170-176.
15. Huang S, Ingber DE, (1999) The structural and mechanical complexity of cell-growth control. Nature Cell Biology 1: E131-138.
16. Capo-chichi CD, Cai KQ, Smedberg J, Ganjei-Azar P, Godwin AK, et al. (2011) Loss of A-type lamin expression compromises nuclear envelope integrity in breast cancer. Chin J Cancer 30: 415-425.
17. Kilian KA, Bugarija B, Lahn BT, Mrksich M, (2010) Geometric cues for directing the differentiation of mesenchymal stem cells. PNAS 107: 4872-4877.
18. Chen CS, Mrksich M, Huang S, Whitesides GM, Ingber DE, (1997) Geometric control of cell life and death. Science 276: 1425-1428.
19. Chen CS, Mrksich M, Huang S, Whitesides GM, Ingber DE, (1998) Micropatterned surfaces for control of cell shape, position, and function. Biotechnology Progress 14: 356-363.
20. Wils J, Geuns H, Baak J, (1988) Proposal for therapeutic approach based on prognostic factors including morphometric and flow-cytometric features in stage III-IV ovarian cancer. Cancer 61: 1920-1925.
21. Hsu CY, Kurman RJ, Vang R, Wang TL, Baak J, et al. (2005) Nuclear size distinguishes low- from high-grade ovarian serous carcinoma and predicts outcome. Human Pathology 36: 1049-1054.
22. TCGA, (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474: 609-615.
23. Nafe R, Franz K, Schlote W, Schneider B, (2005) Morphology of tumor cell nuclei is significantly related with survival time of patients with glioblastomas. Clinical Cancer Research 11: 12141-12148.
24. Bernardini M, Lee CH, Beheshti B, Prasad M, (2005) High-resolution mapping of genomic imbalance and identification of gene expression profiles associated wtih differential chemotherapy response in serous epithelial ovarian cancer. Neoplasia 7: 603-613.
25. Goldie JH, Coldman AJ, (1979) A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 63: 1727-1733.
26. Diest PJ, Baak J, (1991) The morphometric prognostic index is the strongest prognosticator in premenopausal lymph node-negative and lymph node-postiive breast cancer patients. Human Pathology 22: 326-330.
27. Ritter N, Cooper J, (2009) New resolution independent measures of circularity. Journal of Mathematical Imaging and Vision 35: 117-127.
28. Gandhi KS, McKay FC, Diefenbach E, Arthur JW, (2010) Novel approaches to detect serum biomarkers for clinical response to interferon-beta treatment in multiple sclerosis. PloS One 5: e10484-e10493.
29. Dalakas E, Newsome PN, Harrison DJ, Plevris JN, (2005) Hematopoietic stem cell trafficking in liver injury. FASEB J 19: 1225-1231.
30. Park MJ, Kwak HJ, Lee HC, Yoo DH, Hong SI, (2007) Nerve growth factor induces endothelial cell invasion and cord formation by promoting matrix metalloproteinase02 expression through the phosphatidylinositol 3-kinase/Akt signalin pathway and AP-2 transcription factor. J Biol Chem 282: 30485-30496.
31. Kashiwagi Y, Kato N, Sassa T, Yamashita H, (2010) Cotylenin A inhibits cell proliferation and induces apoptosis and PAX6 mRNA transcripts in retinoblastoma cell lines. Mol Vis 16: 970-982.
32. Tothill RW, Tinker AV, George J, Brown R, Bowtell D, (2008) Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 14: 5198-5208.
33. Best CJ, Gillespie JW, Yi Y, Chandramouli GV, Perlmutter MA, et al. (2005) Molecular alterations in primary prostate cancer after androgen ablation therapy. Clinical Cancer Research 11: 6823-6834.
34. Golub TR, Slonim DK, Tamayo P, Lander ES, (1999) Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286: 531-537.
35. Pomeroy SL, Tamayo P, Gaasenbeek M, Sturla LM, Angelo M, (2002) Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 415: 436-442.
36. Abramoff MD, Magelhaes PJ, Ram SJ, (2004) Image processing with ImageJ. Biophotonics Internatonal 11: 36-42.
37. Fischer M, Uchida S, Messlinger K, (2010) Measurement of meningeal blood vessel diameter in vivo with a plug-in for ImageJ. Microvascular Research 80: 258-266.
38. Lysetska M, Knoll A, Boehringer D, Hey T, Krausch G, (2002) UV light-damaged DNA and its interaction with human replication protein A: an atomic force microscopy study. Nucleic Acids Research 30: 2686-2691.
39. National Institutes of Health website. The ImageJ User Guide- IJ 1.45. Available: imagej.nih.gov/ij/docs/guide/. Accessed 2011 Nov 29.
40. Jarque CM, Bera AK, (1987) A test for normality of observations and regression residuals. International Statistical Review 55: 163-172.
41. Benjamini Y, Hochberg Y, (1995) Controlling the false discovery rate: A practical and powerful approach to multiple testing. Journal of the Royal Statistical Society 57: 289-300.